I've been prescribing antidepressants for over a decade in psychiatric care, and treatment-resistant depression (TRD) remains one of the most frustrating clinical scenarios I encounter. You've tried two adequate medication trials. Nothing stuck. Your functioning is impaired, your risk is elevated, and we're running out of conventional options.
So when a new review in Annals of Medicine and Surgery lands on my desk promising rapid remission with psilocybin-assisted therapy, I pay attention. But I also know better than to mistake early promise for established practice.
Here's what the evidence actually shows right now.
The Appeal Is Real
Psilocybin-assisted therapy is mechanistically different from the serotonin reuptake inhibitors and tricyclics we've been refining for decades. It combines transient 5-HT2A receptor agonism with structured psychological support in supervised sessions. Early randomized trials show rapid symptom reductions and encouraging short-term remission rates.
That rapid part matters. Most antidepressants take weeks to work, if they work at all. Psilocybin can show benefit within days.
The problem? Most of that data comes from people with major depressive disorder, not specifically from treatment-resistant populations. The TRD evidence is emerging, but it's not robust yet.
The Central Question Isn't "Does It Work?"
It's "Does it keep working, and at what cost?"
This review nails the issue: we don't have good answers on durability beyond several weeks. We don't know what repeated dosing looks like over time. We don't know if the infrastructure required (multiple hours of supervised sessions, trained therapists, medical oversight) can scale in a way that makes this accessible outside academic centers.
And we're not comparing apples to apples. Where are the head-to-head trials against esketamine, electroconvulsive therapy, or transcranial magnetic stimulation? Those are the actual clinical alternatives when someone walks into my office with TRD.
The Methodology Problems
Sample sizes are modest. Follow-up periods are short. Blinding is nearly impossible when someone is tripping for six hours. That doesn't invalidate the research, but it does mean we need to stay cautious about what we claim.
The review also points out something I see constantly in TRD populations: heterogeneity. Treatment resistance isn't one thing. It's a label we apply to people who didn't respond to prior treatments, but those people have wildly different clinical pictures, comorbidities, trauma histories, and social contexts. Lumping them together makes it harder to know who actually benefits.
What This Means for Practice
I'm not prescribing psilocybin in New Mexico right now because it's not approved for clinical use outside of research settings. But I'm watching this space closely.
If you're struggling with TRD, I want you to know that new mechanisms are being studied. That's legitimately hopeful. But I also want you to be skeptical of hype. The current evidence supports cautious optimism, not certainty.
We need longer trials. We need better comparators. We need cost-effectiveness data and safety monitoring that extends beyond a few months. We need to figure out who benefits most and how often dosing should occur.
The fact that psilocybin works differently from traditional antidepressants is exciting. The fact that we don't yet know how to integrate it into routine care, or whether its effects are durable, is the reality.
I'll keep reading the literature. You should keep asking questions.
Kevin Lazar, MSN, APRN, PMHNP-BC · WellnessRx · View the study
If you are in crisis, call or text 988 (Suicide & Crisis Lifeline). Medications prescribed only when clinically appropriate. Individual results vary. Telehealth services available to New Mexico residents.